Analysis of self-inactivating lentiviral vector integration sites and flanking gene expression in human peripheral blood progenitor cells after alkylator chemotherapy

Human Gene Therapy

Volumn 21, Issue 8, 2010, Pages 943-956

  Grund, N ^a,b   Maier, P ^a,b   Giordano, F A ^a,b   Appelt, J U ^c   Zucknick, M ^b   Li, L ^a   Wenz, F ^a   Zeller, W J ^a,b   Fruehauf, S ^d   Allgayer, H ^a,b   Laufs, S ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Paracelsus Klinik Osnabruck   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; LENTIVIRUS VECTOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ARTICLE; CD34 SELECTION; DNA FLANKING REGION; DOWN REGULATION; DRUG INACTIVATION; GENE EXPRESSION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; PROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS DNA CELL DNA INTERACTION;

ANTIGENS, CD34; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD CELLS; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HUMANS; LENTIVIRUS; POLYMERASE CHAIN REACTION; TERMINAL REPEAT SEQUENCES; TRANSDUCTION, GENETIC; TRANSGENES;

EID: 77955506450     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.116     Document Type: Article

References (85)

1. Abel, U., Deichmann, A., Bartholomae, C., Schwarzwaelder, K., Glimm, H., Howe, S., Thrasher, A., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Fischer, A., Jaeger, D., von Kalle, C., and Schmidt, M. (2007). Real-time definition of non-randomness in the distribution of genomic events. PloS One 2, e570.
2. Aiuti, A., Slavin, S., Aker, M., Ficara, F., Deola, S., Mortellaro, A., Morecki, S., Andolfi, G., Tabucchi, A., Carlucci, F., Marinello, E., Cattaneo, F., Vai, S., Servida, P., Miniero, R., Roncarolo, M.G., and Bordignon, C. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 296, 2410-2413.
3. Akagi, K., Suzuki, T., Stephens, R.M., Jenkins, N.A., and Cope-land, N.G. (2004). RTCGD: Retroviral tagged cancer gene database. Nucleic Acids Res. 32, D523-D527.
4. Al-Kandari, W., Koneni, R., Navalgund, V., Aleksandrova, A., Jambunathan, S., and Fontes, J.D. (2007). The zinc finger proteins ZXDA and ZXDC form a complex that binds CIITA and regulates MHC II gene transcription. J. Mol. Biol. 369, 1175-1187. (Pubitemid 46770777)
5. Appelt, J.U., Giordano, F.A., Ecker, M., Roeder, I., Grund, N., Hotz-Wagenblatt, A., Opelz, G., Zeller, W.J., Allgayer, H., Fruehauf, S., and Laufs, S. (2009). QuickMap: A public tool for large-scale gene therapy vector insertion site mapping and analysis. Gene Ther. 16, 885-893.
6. Baum, C., Dullmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D.A., and von Kalle, C. (2003). Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101, 2099-2114. (Pubitemid 36302043)
7. P140K gene-modified dog hematopoietic cells in primary and secondary recipients. Blood 113, 5094-5103.
8. Benjamini, Y., and Hochberg, Y. (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. 57, 289-300.
9. Bester, A.C., Schwartz, M., Schmidt, M., Garrigue, A., Hacein-Bey-Abina, S., Cavazzana-Calvo, M., Ben-Porat, N., von Kalle, C., Fischer, A., and Kerem, B. (2006). Fragile sites are preferential targets for integrations of MLV vectors in gene therapy. Gene Ther. 13, 1057-1059.
10. Binladen, J., Gilbert, M.T., Bollback, J.P., Panitz, F., Bendixen, C., Nielsen, R., and Willerslev, E. (2007). The use of coded PCR primers enables high-throughput sequencing of multiple ho-molog amplification products by 454 parallel sequencing. PLoS One 2, e197.
11. Boztug, K., Dewey, R.A., and Klein, C. (2006). Development of hematopoietic stem cell gene therapy for Wiskott-Aldrich syndrome. Curr. Opin. Mol. Ther. 8, 390-395.
12. Breitling, R., Armengaud, P., Amtmann, A., and Herzyk, P. (2004). Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 573, 83-92.
13. Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C.C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., Mahlaoui, N., Kiermer, V., Mittelstaedt, D., Bellesme, C., Lahlou, N., Lefrere, F., Blanche, S., Audit, M., Payen, E., Leboulch, P., l'Homme, B., Bougneres, P., von Kalle, C., Fischer, A., Cavazzana-Calvo, M., and Aubourg, P. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326, 818-823.
14. Cassani, B., Montini, E., Maruggi, G., Ambrosi, A., Mirolo, M., Selleri, S., Biral, E., Frugnoli, I., Hernandez-Trujillo, V., Di Serio, C., Roncarolo, M.G., Naldini, L., Mavilio, F., and Aiuti, A. (2009). Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy. Blood 114, 3546-3556.
15. n repeat element within the 5 untranslated region of the FMR1 message provides both positive and negative cis effects on in vivo translation of a downstream reporter. Hum. Mol. Genet. 12, 3067-3074.
16. 6-benzylguanine and 1,3-bis(2-chloroethyl)- nitrosourea or temozolomide. Hum. Gene Ther. 15, 758-769.
17. 6-methylguanine- DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J. Clin. Oncol. 25, 1470-1475.
18. Clopper, C.J., and Pearson, E.S. (1934). The use of confidence or fiducial limits illustrated in the case of the binomial. Biome-trika 26, 404-413.
19. D'Agostino, R.B., and Stephens, M.A. (1986). Goodness-of-Fit Techniques (Marcel Dekker, New York
20. Deichmann, A., Hacein-Bey-Abina, S., Schmidt, M., Garrigue, A., Brugman, M.H., Hu, J., Glimm, H., Gyapay, G., Prum, B., Fraser, C.C., Fischer, N., Schwarzwaelder, K., Siegler, M.L., de Ridder, D., Pike-Overzet, K., Howe, S.J., Thrasher, A.J., Wagemaker, G., Abel, U., Staal, F.J., Delabesse, E., Villeval, J.L., Aronow, B., Hue, C., Prinz, C., Wissler, M., Klanke, C., Weissenbach, J., Alexander, I., Fischer, A., von Kalle, C., and Cavazzana-Calvo, M. (2007). Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J. Clin. Invest. 117, 2225-2232.
21. Demaison, C., Parsley, K., Brouns, G., Scherr, M., Battmer, K., Kinnon, C., Grez, M., and Thrasher, A.J. (2002). High-level transduction and gene expression in hematopoietic re-populating cells using a human immunodeficiency [correction of imunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum. Gene Ther. 13, 803-813.
22. Dennis, G., Jr., Sherman, B.T., Hosack, D.A., Yang, J., Gao, W., Lane, H.C., and Lempicki, R.A. (2003). DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4, 3.
23. 6-benzylguanine and its effect on the sensitivity of a human glioma tumor to 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea. Cancer Commun. 2, 371-377.
24. Emery, D.W., Yannaki, E., Tubb, J., Nishino, T., Li, Q., and Stamatoyannopoulos, G. (2002). Development of virus vectors for gene therapy of b chain hemoglobinopathies: Flanking with a chromatin insulator reduces g-globin gene silencing in vivo. Blood 100, 2012-2019.
25. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 18, 3522-3528.
26. Fruehauf, S., Breems, D.A., Knaan-Shanzer, S., Brouwer, K.B., Haas, R., Lowenberg, B., Nooter, K., Ploemacher, R.E., Valerio, D., and Boesen, J.J. (1996). Frequency analysis of multidrug resistance-1 gene transfer into human primitive hematopoietic progenitor cells using the cobblestone area-forming cell assay and detection of vector-mediated P-glycoprotein expression by rhodamine-123. Hum. Gene Ther. 7, 1219-1231.
27. Futreal, P.A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., and Stratton, M.R. (2004). A census of human cancer genes. Nat. Rev. Cancer 4, 177-183.
28. Gabriel, R., Paruzynski, A., Eckenberg, R., Bartholomae, C.C., Nowrouzu, A., Wang, W., Schwarzwaelder, K., Arens, A., Kirsten, R., Deichmann, A., Ball, C.R., Howe, S.J., Recchia, A., Cattoglio, C., Balaggan, K.S., Yáñez-Muñ oz, R., Ali, R.R., Mavilio, F., Gaspar, H.B., Thrasher, A., Glimm, H., von Kalle, C., Saurin, W., and Schmidt, M. (2008) Assessing the genome accessibility of viral integration sites [abstract]. Hum. Gene Ther. 19, 1085.
29. 6- alkylguanine-DNA alkyltransferase activity in human myeloid cells. J. Clin. Invest. 76, 2106-2114.
30. 6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) in a human colon cancer xenograft completely resistant to BCNU alone. Biochem. Pharmacol. 45, 483-491.
31. Giordano, F.A., Hotz-Wagenblatt, A., Lauterborn, D., Appelt, J.U., Fellenberg, K., Nagy, K.Z., Zeller, W.J., Suhai, S., Frue-hauf, S., and Laufs, S. (2007). New bioinformatic strategies to rapidly characterize retroviral integration sites of gene therapy vectors. Methods Inf. Med. 46, 542-547.
32. \+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor. Stem Cells 24, 1822-1830.
33. Hacein-Bey-Abina, S., Le Deist, F., Carlier, F., Bouneaud, C., Hue, C., De Villartay, J.P., Thrasher, A.J., Wulffraat, N., Sor-ensen, R., Dupuis-Girod, S., Fischer, A., Davies, E.G., Kuis, W., Leiva, L., and Cavazzana-Calvo, M. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193. (Pubitemid 34984579)
34. Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., Asnafi, V., Macintyre, E., Dal, C.L., Radford, I., Brousse, N., Sigaux, F., Moshous, D., Hauer, J., Borkhardt, A., Belohradsky, B.H., Wintergerst, U., Velez, M.C., Leiva, L., Sorensen, R., Wulffraat, N., Blanche, S., Bushman, F.D., Fischer, A., and Cavazzana-Calvo, M. (2008). Insertional on-cogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118, 3132-3142.
35. Hargrove, P.W., Kepes, S., Hanawa, H., Obenauer, J.C., Pei, D., Cheng, C., Gray, J.T., Neale, G., and Persons, D.A. (2008). Globin lentiviral vector insertions can perturb the expression of endogenous genes in b-thalassemic hematopoietic cells. Mol. Ther. 16, 525-533.
36. Hegi, M.E., Diserens, A.C., Gorlia, T., Hamou, M.F., de Tribolet, N., Weller, M., Kros, J.M., Hainfellner, J.A., Mason, W., Mar-iani, L., Bromberg, J.E., Hau, P., Mirimanoff, R.O., Cairncross, J.G., Janzer, R.C., and Stupp, R. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003.
37. Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scand. J. Stat. 6, 65-70.
38. Howe, S.J., Mansour, M.R., Schwarzwaelder, K., Bartholomae, C., Hubank, M., Kempski, H., Brugman, M.H., Pike-Overzet, K., Chatters, S.J., de Ridder, D., Gilmour, K.C., Adams, S., Thornhill, S.I., Parsley, K.L., Staal, F.J., Gale, R.E., Linch, D.C., Bayford, J., Brown, L., Quaye, M., Kinnon, C., Ancliff, P., Webb, D.K., Schmidt, M., von Kalle, C., Gaspar, H.B., and Thrasher, A.J. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest. 118, 3143-3150.
39. Huang, D.W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
40. P140K into hematopoietic stem cells. Cancer Gene Ther. 9, 737-746.
41. Kent, W.J. (2002). BLAT: The BLAST-Like Alignment Tool. Genome Res. 12, 656-664.
42. Kustikova, O., Fehse, B., Modlich, U., Yang, M., Dullmann, J., Kamino, K., von Neuhoff, N., Schlegelberger, B., Li, Z., and Baum, C. (2005). Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking. Science 308, 1171-1174.
43. Kustikova, O.S., Baum, C., and Fehse, B. (2008). Retroviral integration site analysis in hematopoietic stem cells. Methods Mol. Biol. 430, 255-267.
44. Larochelle, A., Choi, U., Shou, Y., Naumann, N., Loktionova, N.A., Clevenger, J.R., Krouse, A., Metzger, M., Donahue, R.E., Kang, E., Stewart, C., Persons, D., Malech, H.L., Dunbar, C.E., and Sorrentino, B.P. (2009). In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. J. Clin. Invest. 119, 1952-1963.
45. Laufs, S., Gentner, B., Nagy, K.Z., Jauch, A., Benner, A., Naun-dorf, S., Kuehlcke, K., Schiedlmeier, B., Ho, A.D., Zeller, W.J., and Fruehauf, S. (2003). Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells. Blood 101, 2191-2198.
46. Laufs, S., Guenechea, G., Gonzalez-Murillo, A., Zsuzsanna, N.K., Luz Lozano, M., del Val, C., Jonnakuty, S., Hotz-Wagenblatt, A., Jens, Z.W., Bueren, J.A., and Fruehauf, S. (2006). Lentiviral vector integration sites in human NOD/SCID repopulating cells. J. Gene Med. 8, 1197-1207.
47. Li, C.L., Xiong, D., Stamatoyannopoulos, G., and Emery, D.W. (2009). Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator. Mol. Ther. 17, 716-724.
48. Li, Z., Dullmann, J., Schiedlmeier, B., Schmidt, M., von Kalle, C., Meyer, J., Forster, M., Stocking, C., Wahlers, A., Frank, O., Ostertag, W., Kuhlcke, K., Eckert, H.G., Fehse, B., and Baum, C. (2002). Murine leukemia induced by retroviral gene marking. Science 296, 497.
49. \+ hematopoietic progenitor cells. Radiat. Res. 169, 301-310.
50. P140K. Gene Ther. 17, 389-399.
51. Margulies, M., Egholm, M., Altman, W.E., Attiya, S., Bader, J.S., Bemben, L.A., Berka, J., Braverman, M.S., Chen, Y.J., Chen, Z., Dewell, S.B., Du, L., Fierro, J.M., Gomes, X.V., Godwin, B.C., He, W., Helgesen, S., Ho, C.H., Irzyk, G.P., Jando, S.C., Alenquer, M.L., Jarvie, T.P., Jirage, K.B., Kim, J.B., Knight, J.R., Lanza, J.R., Leamon, J.H., Lefkowitz, S.M., Lei, M., Li, J., Lohman, K.L., Lu, H., Makhijani, V.B., McDade, K.E., McKenna, M.P., Myers, E.W., Nickerson, E., Nobile, J.R., Plant, R., Puc, B.P., Ronan, M.T., Roth, G.T., Sarkis, G.J., Simons, J.F., Simpson, J.W., Srinivasan, M., Tartaro, K.R., Tomasz, A., Vogt, K.A., Volkmer, G.A., Wang, S.H., Wang, Y., Weiner, M.P., Yu, P., Begley, R.F., and Rothberg, J.M. (2005). Genome sequencing in microfabricated high-density picolitre reactors. Nature 437, 376-380.
52. Maruggi, G., Porcellini, S., Facchini, G., Perna, S. K., Cattoglio, C., Sartori, D., Ambrosi, A., Schambach, A., Baum, C., Bonini, C., Bovolenta, C., Mavilio, F., and Recchia, A. (2009). Tran-scriptional enhancers induce insertional gene deregulation independently from the vector type and design. Mol. Ther. 17, 851-856.
53. 6-methylguanine-DNA methyltransferase P140K expression level and chemoprotec-tion of hematopoietic stem cells. Cancer Res. 68, 6171-6180.
54. Mitchell, R.S., Beitzel, B.F., Schroder, A.R., Shinn, P., Chen, H., Berry, C.C., Ecker, J.R., and Bushman, F.D. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. PLoS Biol. 2, e234.
55. Modlich, U., Bohne, J., Schmidt, M., von Kalle, C., Knoss, S., Schambach, A., and Baum, C. (2006). Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood 108, 2545-2553.
56. Modlich, U., Schambach, A., Brugman, M.H., Wicke, D.C., Knoess, S., Li, Z., Maetzig, T., Rudolph, C., Schlegelberger, B., and Baum, C. (2008). Leukemia induction after a single ret-roviral vector insertion in Evi1 or Prdm16. Leukemia 22, 1519-1528.
57. Montini, E., Cesana, D., Schmidt, M., Sanvito, F., Bartholomae, C.C., Ranzani, M., Benedicenti, F., Sergi, L.S., Ambrosi, A., Ponzoni, M., Doglioni, C., Di Serio, C., von Kalle, C., and Naldini, L. (2009). The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest. 119, 964-975.
58. Neff, T., Beard, B.C., Peterson, L.J., Anandakumar, P., Thompson, J., and Kiem, H.P. (2005). Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105, 997-1002.
59. Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., Hoffman, R., Stevens, M.F., Brampton, M.H., and Gibson, A.C. (1992). Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65, 287-291.
60. Ott, M.G., Schmidt, M., Schwarzwaelder, K., Stein, S., Siler, U., Koehl, U., Glimm, H., Kuhlcke, K., Schilz, A., Kunkel, H., Naundorf, S., Brinkmann, A., Deichmann, A., Fischer, M., Ball, C., Pilz, I., Dunbar, C., Du, Y., Jenkins, N.A., Copeland, N.G., Luthi, U., Hassan, M., Thrasher, A.J., Hoelzer, D., von Kalle, C., Seger, R., and Grez, M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med. 12, 401-409.
61. 6-alkylguanine-DNA alkyl-transferase: Regulation and importance in response to alky-lating carcinogenic and therapeutic agents. Cancer Res. 50, 6119-6129.
62. Phillips, G.L., Fay, J.W., Herzig, G.P., Herzig, R.H., Weiner, R.S., Wolff, S., Lazarus, H.M., Karanes, C., Ross, W.E., and Kramer, B.S. (1983). Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer: A phase I-II study. Cancer 52, 1792-1802.
63. Phillips, G.L., Wolff, S.N., Fay, J.W., Herzig, R.H., Lazarus, H.M., Schold, C., and Herzig, G.P. (1986). Intensive 1,3-bis (2-chloroethyl)-1- nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma. J. Clin. Oncol. 4, 639-645.
64. Popescu, N.C. (2003). Genetic alterations in cancer as a result of breakage at fragile sites. Cancer Lett. 192, 1-17.
65. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol. 23, 7178-7187.
66. 6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin. Cancer Res. 15, 1064-1068.
67. Ragg, S., Xu-Welliver, M., Bailey, J., D'Souza, M., Cooper, R., Chandra, S., Seshadri, R., Pegg, A.E., and Williams, D.A. (2000). Direct reversal of DNA damage by mutant methyl-transferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60, 5187-5195.
68. 6-alkylguanine-DNA-alkyltransferase: Phase I safety, phar-macodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 12, 1577-1584.
69. Recchia, A., Bonini, C., Magnani, Z., Urbinati, F., Sartori, D., Muraro, S., Tagliafico, E., Bondanza, A., Stanghellini, M.T., Bernardi, M., Pescarollo, A., Ciceri, F., Bordignon, C., and Mavilio, F. (2006). Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells. Proc. Natl. Acad. Sci. U.S.A. 103, 1457-1462.
70. 6-benzylgua-nine, and an alkyltransferase-expressing retroviral vector. Mol. Ther. 3, 78-87.
71. Schambach, A., and Baum, C. (2008). Clinical application of lentiviral vectors: Concepts and practice. Curr. Gene Ther. 8, 474-482.
72. Schilz, A.J., Schiedlmeier, B., Kuhlcke, K., Fruehauf, S., Linde-mann, C., Zeller, W.J., Grez, M., Fauser, A.A., Baum, C., and Eckert, H.G. (2000). MDR1 gene expression in NOD/SCID repopulating cells after retroviral gene transfer under clinically relevant conditions. Mol. Ther. 2, 609-618.
73. Schroder, A.R., Shinn, P., Chen, H., Berry, C., Ecker, J.R., and Bushman, F. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-529.
74. Seggewiss, R., Pittaluga, S., Adler, R.L., Guenaga, F.J., Ferguson, C., Pilz, I.H., Ryu, B., Sorrentino, B.P., Young, W.S., III, Donahue, R.E., von Kalle, C., Nienhuis, A.W., and Dunbar, C.E. (2006). Acute myeloid leukemia is associated with ret-roviral gene transfer to hematopoietic progenitor cells in a rhesus macaque. Blood 107, 3865-3867.
75. Smith, D.C., Gerson, S.L., Liu, L., Donnelly, S., Day, R., Trump, D.L., and Kirkwood, J.M. (1996). Carmustine and streptozocin in refractory melanoma: An attempt at modulation of O-alkylguanine-DNA-alkyltransferase. Clin. Cancer Res. 2, 1129-1134.
76. Sorrentino, B.P. (2002). Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat. Rev. Cancer 2, 431-441.
77. Stephens, M.A. (1974). EDF statistics for goodness of fit and some comparisons. J. Am. Stat. Assoc. 69, 730-737.
78. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Ei-senhauer, E., and Mirimanoff, R.O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
79. Terskikh, A.V., Ershler, M.A., Drize, N.J., Nifontova, I.N., and Chertkov, J.L. (2005). Long-term persistence of a noninte-grated lentiviral vector in mouse hematopoietic stem cells. Exp. Hematol. 33, 873-882.
80. 6- Alkylguanine-DNA alkyltransferase activity in human brain and brain tumors. Carcinogenesis 5, 121-124.
81. Wu, X., Li, Y., Crise, B., and Burgess, S.M. (2003). Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-1751.
82. 6-benzylguanine. Cancer Res. 59, 1514-1519.
83. Zaiss, A.K., Son, S., and Chang, L.J. (2002). RNA 3 readthrough of oncoretrovirus and lentivirus: Implications for vector safety and efficacy. J. Virol. 76, 7209-7219.
84. \+ hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Mol. Ther. 5, 381-387.
85. Zychlinski, D., Schambach, A., Modlich, U., Maetzig, T., Meyer, J., Grassman, E., Mishra, A., and Baum, C. (2008). Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther. 16, 718-725.